2023 World Conference on Lung Cancer (Posters)-EP08.02. Real World Chemoradiotherapy Outcomes for Frail Older Adults with Unresectable Stage III Non Small Cell Lung Cancer (NSCLC)

EP08.02. Real World Chemoradiotherapy Outcomes for Frail Older Adults with Unresectable Stage III Non Small Cell Lung Cancer (NSCLC) - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to examine the impact of frailty on treatment outcomes for older adults with stage III non-small cell lung cancer (NSCLC). The researchers conducted a retrospective audit of patients over the age of 65 who received chemoradiotherapy between June 2017 and December 2021. Frailty was assessed using a 58-item frailty index (FI) prior to initial specialist consultation. Treatment outcomes evaluated included chemotherapy completion, radiotherapy completion, initiation of durvalumab (a medication used to treat lung cancer), and overall survival.<br /><br />A total of 29 patients were included in the study, with a median age of 73. Approximately 41% of the patients were classified as frail based on the FI assessment. The results showed that frail patients were less likely to complete all planned cycles of chemotherapy compared to fit patients (50% vs 88%). However, both frail and fit patients had similar rates of initiating durvalumab (75% vs 82%). The estimated median overall survival was 38.7 months, and the median progression-free survival was 17.5 months. Frailty was found to be a predictor of mortality but not progression.<br /><br />The study findings suggest that patients with higher baseline frailty scores may have inferior survival outcomes compared to those with lower frailty scores. Further research is needed to determine if the frailty index can be a reliable predictor of toxicities and survival outcomes in this population. Overall, the study sheds light on the importance of considering frailty in the treatment of older adults with stage III NSCLC.

Asset Subtitle

Nicole Pringle

Meta Tag

Speaker Nicole Pringle

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

frailty

treatment outcomes

older adults

stage III non-small cell lung cancer

NSCLC

chemoradiotherapy

retrospective audit

frailty index

chemotherapy completion

radiotherapy completion